Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Sasaki, Ryu ^a   Yamasaki, Kazumi ^a   Abiru, Seigo ^a   Komori, Atsumasa ^a   Nagaoka, Shinya ^a   Saeki, Akira ^a   Hashimoto, Satoru ^a   Bekki, Shigemune ^a   Kugiyama, Yuki ^a   Kuno, Atsushi ^b   Korenaga, Masaaki ^c   Togayachi, Akira ^b   Ocho, Makoto ^b   Mizokami, Masashi ^c   Narimatsu, Hisashi ^b   Ichikawa, Tatsuki ^d   Nakao, Kazuhiko ^d   Yatsuhashi, Hiroshi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BINDING PROTEIN; INTERFERON; MAC 2 BINDING PROTEIN; PEGINTERFERON; PLANT LECTIN; RIBAVIRIN; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ; ANTIVIRUS AGENT; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; WISTERIA LECTIN;

ADULT; AGE DISTRIBUTION; AGED; AGGLUTININ BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; WISTERIA; WISTERIA FLORIBUNDA; ADOLESCENT; BIOPSY; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

HEPATITIS C VIRUS; WISTERIA; WISTERIA FLORIBUNDA;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; ANTIVIRAL AGENTS; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, HEPATOCELLULAR; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLANT LECTINS; PROGNOSIS; RECEPTORS, N-ACETYLGLUCOSAMINE; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84936147439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129053     Document Type: Article

References (49)

1. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255. doi: 10.1016/S0140-6736(11)61347-0 PMID: 22353262
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714. PMID: 16702586
3. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. (2004) Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127(Suppl): S17-26.
4. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333-1342. doi: 10.1002/hep.26141 PMID: 23172780
5. Thomas DL, Seeff LB (2005) Natural history of hepatitis C. Clin Liver Dis 9: 383-398. PMID: 16023972
6. Sherman M (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154. PMID: 15918143
7. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576. PMID: 17570226
8. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS (2010) A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 8: 280-288,288.e1. doi: 10.1016/j.cgh.2009.11.018 PMID: 19948249
9. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, et al.: HENCORE Group (2007) Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 14: 556-563. PMID: 17650289
10. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnú L, Mazzella G, et al.: Italian Association of the Study of the Liver Disease (AISF) (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45: 579-587. PMID: 17326216
11. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9: 509-516. doi: 10.1016/j.cgh.2011.03.004 PMID: 21397729
12. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter. (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158: 329-337. doi: 10.7326/0003-4819-158-5-201303050-00005 PMID: 23460056
13. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131: 174-181. PMID: 10428733
14. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. (2010) Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52: 518-527. doi: 10.1002/hep.23691 PMID: 20683951
15. Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, et al. (2005) Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 20: 752-758. PMID: 15853990
16. Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, et al. (2004) Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 24: 603-610. PMID: 15566511
17. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. (2007) Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 27: 186-191. PMID: 17311612
18. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. (2005) Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 40: 148-156. PMID: 15770398
19. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. (2004) Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101: 1616-1622. PMID: 15378504
20. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. (2013) A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 3: 1065. doi: 10.1038/srep01065 PMID: 23323209
21. Narimatsu Y, Kuno A, Ito H, Kaji H, Kaneko S, Usui J, et al. (2014) IgA nephropathy caused by unusual polymerization of IgA1 with aberrant N-glycosylation in a patient with monoclonal immunoglobulin deposition disease. PloS One 9: e91079. doi: 10.1371/journal.pone.0091079 PMID: 24651839
22. Sasaki T, Brakebusch C, Engel J, Timpl R (1998) Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 17: 1606-1613. PMID: 9501082
23. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M, et al. (2001) Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alphafetoprotein. Clin Chem Lab Med 39: 961-965. PMID: 11758611
24. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, et al. (1996) Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 25: 212-217. PMID: 8878784
25. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H (2009) The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 16: 418-429. doi: 10.1111/j.1365-2893.2009.01083.x PMID: 19226329
26. Kuno A, Sato T, Shimazaki H, Unno S, Saitou K, Kiyohara K, et al. (2013) Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 7: 642-647.
27. Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, et al. (2011) Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 46: 92-100. doi: 10.1007/s00535-010-0293-6 PMID: 20711614
28. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. (2014) Elevated serum levels of WFA+ -M2BP predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 60: 1563-70. doi: 10.1002/hep.27305 PMID: 25042054
29. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520. PMID: 8188183
30. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391-2399. PMID: 8245854
31. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. (1997) New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35: 201-207. PMID: 8968908
32. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344. PMID: 10877287
33. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, et al. (2007) Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 13: 5180-5187. PMID: 17876888
34. Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martínez-Tlahuel JL, et al. (2007) Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. Clin Oncol 19: 197-203.
35. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43: 434-441. PMID: 16136646
36. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, et al. (2013) α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 58: 1253-1262. doi: 10.1002/hep.26442 PMID: 23564522
37. Hasegawa E, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. (2007) Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res 37: 793-800. PMID: 17593231
38. Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al.: PERFECT Study Group (2011) Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. Hepatol Res 41: 955-964. doi: 10.1111/j.1872-034X.2011.00847.x PMID: 21707888
39. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama, et al.: Kyushu University Liver Disease Study (KULDS) Group (2013) Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 58: 495-501. doi: 10.1016/j.jhep.2012.10.017 PMID: 23099187
40. Shindo M, Hamada K, Oda Y, Okuno T (2001) Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 33: 1299-1302. PMID: 11343259
41. Kim KI, Sasase N, Taniguchi M, Mita K, Kim SR, Tanaka K, et al. (2005) Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification. Intervirology. 48: 52-58. PMID: 15785090
42. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al.: HALT-C Trial Group (2010) Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52: 833-844. doi: 10.1002/hep.23744 PMID: 20564351
43. Hu J, He J, Kuang Y, Wang Z, Sun Z, Zhu H, et al. (2013) Expression and significance of 90K/Mac-2BP in prostate cancer. Exp Ther Med 5: 181-184. PMID: 23251263
44. Sun L, Chen L, Sun L, Pan J, Yu L, Han L, et al. (2013) Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. Mol Cell Proteomics 12: 395-406. doi: 10.1074/mcp.M112.020784 PMID: 23184915
45. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209-218. PMID: 15690074
46. Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172. doi: 10.1152/physrev.00013.2007 PMID: 18195085
47. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, et al. (2012) Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 143: 1073-1083. doi: 10.1053/j.gastro.2012.06.036 PMID: 22750464
48. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al.: ION-1 Investigators (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 15: 1889-1898.
49. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al.: ION-2 Investigators (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 17: 1483-1493.